您的位置: 首页 » 法律资料网 » 法律法规 »

Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)

作者:法律资料网 时间:2024-07-01 22:27:44  浏览:9919   来源:法律资料网
下载地址: 点击此处下载

Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)

State Food and Drug Administration General Administration of Customs of the People’s Republic of China


Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)




(SFDA Decree No. 25)

The Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim), adopted by the State Food and Drug Administration, the General Administration of Customs of the People’s Republic of China and the General Administration of Sport of China, is hereby promulgated in the decree sequence number of the State Food and Drug Administration and shall come into force as of September 1, 2006.


Shao Mingli
Commissioner
State Food and Drug Administration

Mou Xinsheng
Minister
General Administration of Customs of the People’s Republic of China

Liu Peng
Minister
General Administration of Sport of China
July 28, 2006





Provisions for Import and Export of Anabolic Agents and Peptide Hormones (Interim)


Article 1 The Provisions are formulated with a view to standardizing the administration of import and export of anabolic agents and peptide hormones in accordance with the Drug Administration Law of the People’s Republic of China, Customs Law of People's Republic of China, Anti-doping Regulations and other relevant laws and administrative regulations.

Article 2 The State adopts license control on the import and export of anabolic agents and peptide hormones.

Article 3 The importer shall apply for the importation of anabolic agents and peptide hormones to the State Food and Drug Administration.

Article 4 For the importation of anabolic agents and peptide hormones for medical purpose, the importers shall submit the following materials:
(1) Application Form for Drug Import;
(2) Copy of the purchasing contract or order form;
(3) Copy of the Import Drug License (or the Pharmaceutical Product License) (original or duplicate);
(4) Copy of the Drug Supply Certificate, Business License for Enterprises as a Legal Person, Qualification Certificate for Import and Export Enterprise (or Foreign Trade Operator Filing and Registration Form) and Organization Code Certificate of the importer; to import drug substance and intermediate preparations including preparations to be repackaged in China for their own needs, drug manufacturers shall submit copies of the Drug Manufacturing Certificate, Corporate Business License and Organization Code Certificate;
(5) Where holders of the Import Drug License (or the Pharmaceutical Product License) entrust other companies to export their drugs, they shall provide the authorization letter for export.

All copies mentioned above should be stamped with the official seal of the importer.

Article 5 For the importation of anabolic agents and peptide hormones for teaching and scientific research purposes, the importers shall submit the following materials:
(1) Application Form for Drug Import;
(2) Copy of the purchasing contract or order form;
(3) Certificates of legitimate qualifications of users in China, calculation basis for the quantity of the drug in use and letter of guarantee issued by the user for legitimate use and management of the drug;
(4) Approval documents for relevant scientific research projects or approval documents of relevant competent authority;
(5) Where entrusted by users for importation, importers shall provide copies of the authorization agreement, the Business License for Enterprises as a Legal Person, Qualification Certificate for Import and Export Enterprise (or Foreign Trade Operator Filing and Registration Form) and Organization Code Certificate of the importers.

All copies mentioned above should be stamped with the official seal of the importer.

Article 6 Where a enterprise in China entrusted by an overseas enterprise for contract manufacturing needs to import anabolic agents and peptide hormones, it shall provide materials required in Items (1), (3) and (5) of Paragraph 1 of Article 5, in addition, official documents to prove recorded by the local (food and) drug regulatory department of the province, autonomous region or municipality directly under the Central Government.

All copies mentioned above should be stamped with the official seal of the importer.

Article 7 The State Food and Drug Administration shall decide whether or not to approve the import within 15 working days after receiving the application for import and the relevant materials. Where the application is approved, the State Food and Drug Administration shall issue the Import License for the drug; where the application is not approved, the State Food and Drug Administration shall give reasons in writing.

Article 8 The importer may declare to the customs of the ports where drug importation is permitted upon presenting the Import License for the drug issued by the State Food and Drug Administration. The customs shall clear the drug in the presence of the Import License for the drug.
The Drug Import Note is not required for import of anabolic agents and peptide hormones.

Article 9 To import anabolic agents and peptide hormones including those sold in China for the first time for medical purpose, the importer shall fill in the Import Drug Clearance Form timely after going through the import formalities and submit the following materials in duplicate to the (food and) drug regulatory department where the port of entry is located, upon presenting the original Import Drug License (or the Pharmaceutical Product License) (original or duplicate) and the original Import License for the drug, to apply for the Notice of Import Drug Port Test:
(1) Copies of the Import Drug License (or Pharmaceutical Product License) (original or duplicate) and the Import License for the drug;
(2) Copies of the Drug Manufacturing Certificate or Drug Supply Certificate, and Copy of the Business License for Enterprises as a Legal Person.
(3) Copy of the certificate of origin;
(4) Copy of the purchasing contract;
(5) Copies of packing list, bill of lading and freight invoice;
(6) Copy of the certificate of analysis;
(7) Format of drug insert sheet, package and label (except for drug substance and intermediate preparation);

All copies mentioned above should be stamped with the official seal of the importer.

Article 10 After checking the received Import Drug Clearance Form and relevant materials, the port (food and) drug regulatory department shall return the original Import Drug License (or Pharmaceutical Product License) (original or duplicate) and the original Import License for the drug to the importer, and send the Notice of Import Drug Port Test, along with a copy of the dossier as prescribed in Article 9 of the Provisions, to the port drug testing institute on the same day.

After receiving the Notice of Import Drug Port Test, the port drug testing institute shall contact the importer within two working days and conduct sampling on the storage site. Upon the completion of the sampling, the mark “sampled” shall be stamped on the back of the first page of the original Import License for the drug, with the seal of sampling institute affixed.

Article 11 Anabolic agents and peptide hormones imported for teaching and research purposes or for the domestic manufacturing contracted by overseas enterprises are exempted from testing.

Article 12 The port (food and) drug regulatory department shall report timely to the State Food and Drug Administration in any of the following circumstances:
(1) The port (food and) drug regulatory department refuses to issue the Notice of Import Drug Port Test in accordance with the provisions in Article 17 of the Provisions for Import Drug (Decree No. 4 of the State Food and Drug Administration and the General Administration of Customs);
(2) The port (food and) drug testing institute refuses the sampling in accordance with the requirements in Article 25 of the Provisions for Import Drug.

The port (food and) drug regulatory department shall take mandatory administrative measures to seal up or seize all the imported drugs within the situations prescribed in the previous paragraph. It shall make the decision of allowing shipping back within seven days from the date of the seal-up or seizure, and inform the importer of applying for the Export License for the drug according to the export procedures for anabolic agents and peptide hormones prescribed in the Provisions and return all the import drugs to the original exporting country.

Where the importer fails to respond or make clear its intention to ship back the drugs within ten days after being informed of the decision, the sealed up or seized drugs shall be destroyed under the supervision of the port (food and) drug regulatory department.

Article 13 For imported anabolic agents and peptide hormones out of specifications upon testing by the port drug testing institute, the importer shall provide a detailed report about the distribution and use of all the imported drugs to the port (food and) drug regulatory department where the importer is located within two days after receiving the Import Drug Test Report.

After receiving the Import Drug Test Report, the port (food and) drug regulatory departments shall take mandatory administrative measures to timely seal up or seize all the drugs and, within seven days, decide whether or not to place the case on file.

Where the importer fails to apply for a retesting within the specified timeline or the result of the retesting is still out of specifications, the port (food and) drug regulatory department shall make the decision of allowing shipping back and notify the importer to apply for the Export License for the drug according to export procedures for anabolic agents and peptide hormones prescribed in the Provisions to return all the imported drugs to the original exporting country. Where the importer fails to respond or make clear its intention to ship back the drugs within ten days from the date of receiving the decision, the drugs shall be destroyed under the supervision of the port (food and) drug regulatory department.

Where the result of retesting is in compliance with the specifications, the port (food and) drug regulatory department shall remove the mandatory administrative measures of seal-up and seizure.

The port (food and) drug regulatory department shall handle the case according to the provisions in Paragraph 2, Paragraph 3 and Paragraph 4 of this Article and report the result to the State Food and Drug Administration, and, at the same time, notify the (food and) drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government as well as other port (food and) drug regulatory departments.

Article 14 Where domestic drug manufacturers, distributors and medical institutions purchase imported anabolic agents and peptide hormones, the supplier shall provide copies of the Import Drug License (or Pharmaceutical Product License), the Import License for the drug and the Import Drug Test Report, and affix its official seal to the abovementioned copies.

Article 15 The exporter shall apply for exportation of anabolic agents and peptide hormones to the (food and) drug regulatory department of the province, autonomous region or municipality directly under the Central Government, where it is located, and submit the following materials:
(1) Application Form for Drug Export;
(2) Original import permit (or its copy with notarization) provided by the drug regulatory authority of the importing country or region.
If the importing country or region has no license system in the importation of anabolic agents and peptide hormones, the exporter shall provide the official document (original) of the drug regulatory authority of the importing country or region to prove that the import of the drugs of this type is exempted from the import permit, along with one of the following documents:
a. Original official document (or its copy with notarization) granting import provided by the drug regulatory authority of the importing country or region;
b. Certificates of legitimate qualifications of importers and original supporting document (or its copy with notarization) proving legitimate use of the drug;
(3) Copy of the purchasing contract or order form (except for manufacturers that export their own products);
(4) Copy of the export contract or order form;
(5) Where the export drug is an approved one produced by a domestic manufacturer, the Drug Manufacturing Certificate and Business License for Enterprises as a Legal Person of the manufacturer and a copy of the approval document of the drug shall be provided;
Where the export drug is produced by a domestic enterprise under contract of an overseas enterprise, the exporter shall provide a copy of the official document to prove recorded by the local (food and) drug regulatory department of the province, autonomous region and municipality directly under the Central Government.
(6) Copies of the Business License for Enterprises as a Legal Person, Qualification Certificate for Import and Export Enterprise (or Foreign Trade Operator Filing and Registration Form) and Organization Code Certificate of the exporter.

All copies mentioned above should be stamped with the official seal of the exporter.

Article 16 Where the drugs are to be shipped back in accordance with the requirements in Article 12 and Article 13 of the Provisions, the exporter shall provide the following materials to apply for the Export License for the drug:
(1) Documents proving the request for return of goods made by the original exporter of the exporting country;
(2) Import License for the drug.

Article 17 The (food and) drug regulatory department of the province, autonomous region and municipality directly under the Central Government shall decide whether or not to approve the export within 15 working days after receiving the export application and relevant materials.

Where the application is approved, the regulatory department shall issue the Export License for the drug; where the application is not approved, the regulatory department shall give reasons in writing.

Where the Export License for the drug is applied for in accordance with the requirements in Article 16 of the Provisions, the issuing authority shall mark “return of the original goods” on the Export License for the drug.

Article 18 The exporter may go through the customs formalities upon presenting the Export License for the drug issued by the (food and) drug regulatory department of the province, autonomous region and municipality directly under the Central Government. The customs shall clear the drug in the presence of the Export License for the drug.

Article 19 The importer and exporter shall provide one more sheet of customs declaration form and apply for sign-back of the sheet when going through the customs formalities. The customs shall stamp the “proof seal” on the sheet in the presence of the Import License for the drug and Export License for the drug. The customs shall charge the cost according to the relevant regulations for issuing certificates.

The importer and exporter shall return the first sheet of the Import License for the drug or Export License for the drug along with the customs declaration form with the seal of the customs, to the issuing regulatory department within one month after completing the import and export.

Where the importer or exporter conducts no relevant importation or exportation after obtaining the Import License for the drug and Export License for the drug, the importer or exporter shall return the original license to the issuing regulatory department within one month after expiration of the license.

Article 20 The validation of the Import License for the drug is one year; the validation of the Export License for the drug is no more than three months (valid within the calendar year).

“One license for one customs clearance” is implemented for the Import License for the drug and Export License for the drug. The license shall be used only once within the validation and its content shall not be altered. Where the import or export is postponed for some reasons, the importer or exporter may request for a new license once with the original one.

Article 21 Where the Import License for the drug or Export License for the drug is lost, the importer or exporter shall report the loss to the original issuing authority in writing immediately. After receiving the loss report, the original issuing authority shall notify the port customs and reissue the license if no harmful consequences are found through confirmation.

Article 22 The Import License for the drug and Export License for the drug are uniformly printed by the State Food and Drug Administration.

Article 23 Where anabolic agents and peptide hormones are imported or exported in the form of processing trade, the customs shall go through and supervise the clearance formalities upon presentation of the Import License for the drug or Export License for the drug. Those not exported for special reasons shall be transferred to and handled by the local (food and) drug regulatory department in accordance with relevant regulations, and the customs shall conduct the verification and cancellation procedures in the presence of relevant documents.

Article 24 Anabolic agents and peptide hormones entering or leaving between bonded zones, export processing zones, other special Customs controlling areas, Customs bonded and controlling areas, with overseas, or between the special Customs controlling areas and the Customs bonded and controlling areas are exempt from application for the Import License for the drug or Export License for the drug, and supervised by the Customs.

Import License for the drug shall be applied for anabolic agents and peptide hormones entering from bonded zones, export processing zones, other special Customs controlling areas and Customs bonded and controlling areas into other places in China.

Export License for the drug shall be applied for anabolic agents and peptide hormones entering bonded zones, export processing zones, other special Customs controlling areas and Customs bonded and controlling areas from other places of China.

Article 25 Where an individual carries or mails anabolic agents and peptide hormones, within a reasonable amount, into or out of China for medical needs, the customs shall clear the drugs in the presence of prescriptions of medical institutions in accordance with relevant regulations on prescriptions of the competent health department.

Article 26 Besides prescribed in the Provisions, the importation, port test, supervision and control of anabolic agents and peptide hormones for medical purpose are implemented with reference to requirements related to drug importation in the Provisions for Drug Importation.

Article 27 Anabolic agents and peptide hormones imported for medical purpose mentioned in the Provisions refer to the import anabolic agents and peptide hormones to be used for preparation production or to be marketed in China.

Importer refers to the importer specified on the Import License for the drug obtained in accordance with the Provisions.

Exporter refers to the exporter specified on the Export License for the drug obtained in accordance with the Provisions.

Article 28 These Provisions shall go into effect as of September 1, 2006. The Notice on Import and Export of Anabolic Agents and Peptide Hormones (Guo Shi Yao Jian An [2004] No. 474) issued by the State Food and Drug Administration on September 30, 2004 shall be annulled therefrom.


下载地址: 点击此处下载
论受贿罪的共犯

刘俊芳
(南京化工职业技术学院社会科学部)


摘要:非特殊身份人员能够构成受贿罪的共犯。作为受贿罪共犯的形式之一,国家工作人员的家属构成受贿罪共犯是有严格界限的。
关键词:非特殊身份人员 受贿罪 共犯
Summary Nowadays ,people have fixed their eyes on the corruption. The body of ribery is special status , non-particular status can ’t consist of it . The people of on-particular status can constitute the accomplice of bribery ,but can ‘ t constitute the common executive offence of bribery .There have the major form in the accomplice of bribery .It have strict limitation that retired national official and national official ‘s kinsfolk consist of the accomplice of bribery .
Keywords non-particular status bribery accomplice
一、非特殊身份人员能否构成受贿罪的共犯
从我国刑法的规定来看,受贿罪的构成要件必须符合下列条件:(1)、主体是特殊主体,即国家工作人员,非国家工作人员不能构成本罪主体。(2)、主观方面是故意行为,过失行为不能构成。(3)、侵犯的客体是国家工作人员职务行为的廉洁性。(4)、客观方面表现为行为人利用职务上的便利。受贿罪的主体和客观方面的特征决定了它是身份犯。所谓身份犯,是指法律规定的以行为人在行为时所具有的特定身份为定罪要件或法定量刑情节的犯罪。受贿罪的身份犯显然是定罪要件。它不同与其他一般主体构成的犯罪。它以国家工作人员作为特殊主体,非国家工作人员不能构成受贿罪。
在受贿罪的共同犯罪中,国家工作人员之间利用职务之便,实施受贿行为。成立受贿的共犯,是毋庸质疑的;国家工作人员与非国家工作人员是否构成受贿的共犯,即身份犯与无身份犯能否构成只有特殊主体资格才能构成的共同犯罪,理论界有不同的看法:
第一种观点认为,非特殊身份人员不能构成受贿罪的共犯。法律依据是全国人大常委会1988年1月21日《关于惩治贪污罪贿赂罪补充规定》第四条第二款规定:“与国家工作人员、集体经济组织的工作人员或者其他从事公务的互相勾结,伙同受贿的,以共犯论处”。在本规定第一条第二款规定:“与国家工作人员、集体经济组织的工作人员或者其他经手管理公共财物的人员相勾结。伙同贪污的,以共犯论处”。而1997年刑法中却只保留了内外勾结的贪污罪共犯,即第三百八十二条第三款:“与前两款所列人员勾结,伙同贪污的,以共犯论处”。实际上等于取消了《补充规定》对受贿罪共犯的规定。本着法无明文规定不为罪的原则,应该认定无身份犯不能构成受贿罪共犯。
第二种观点认为。1997年刑法虽然没有明确规定无身份犯能否构成受贿罪共犯的问题,但在刑法分则无特别规定时,应适用刑法总则关于共同犯罪的规定。这是总则和分则的关系所决定的。参照共同犯罪的有关规定和分则中关于贪污罪共犯的规定,对非国家工作人员与国家工作人员相勾结,伙同受贿的,仍应以受贿罪的共犯追究其刑事责任。
我比较同意第二种观点。除上述理由外,还有以下依据:
1、刑法具有保护社会秩序的价值取向。《刑法》第三百八十二条第三款表明非国家工作人员可以成为贪污罪的共犯。2000年7月8日最高人民法院《关于审理贪污、职务侵占案件如何认定共同犯罪几个问题的解释》第一条规定:“行为人与国家工作人员勾结、利用国家工作人员的职务便利,共同侵吞、窃取、骗取或者以其他手段非法占有公共财物的,以贪污罪共犯论处。”以上法律条文与司法解释都贯穿了这一原则。某些犯罪即使在单独犯罪中只能由特殊主体构成,但在共同犯罪时也可以由无身份犯的普通主体构成。这表明了刑法在对特殊主体以外的其他社会成员个人自由和保护社会秩序二者之间,选择了后者。[1]例如1998年4月最高人民法院《关于审理挪用公款案件具体应用法律若干问题的解释》规定,“挪用公款给他人使用,使用人与挪用人共谋,指使或者参与策划取得挪用款的,以挪用公款罪的共犯定罪处罚。”从这一司法解释,亦可以显见刑法的价值取向:保护社会秩序。无身份的社会人员可以构成挪用公款罪的共犯。贪污罪、挪用公款罪和受贿罪同属贪污贿赂罪的内容。因此,在共同的价值取向下,无身份的人也可以构成受贿罪的共犯。
2、刑法第三百八十二条第三款的内容属于注意规定,而非法定拟制。[2] 对贪污共犯的注意规定只是为了防止司法机关的误判。因为贪污罪包含了利用职务之便的侵吞、窃取、骗取或者其他非法占有公共财物的行为,无身份犯与身份犯相勾结,伙同贪污时,无身份犯的行为也符合侵占罪、盗窃罪和诈骗罪的构成要件。这个注意规定,是为了防止司法人员将贪污共犯认定为侵占、盗窃、诈骗等罪。刑法对受贿罪取消注意规定,是因为基本上不存在将受贿罪共犯认定为其他犯罪的问题。因而没有提醒的必要。刑法具有简洁性的要求,只会把容易产生误解的内容作出注意规定,其他情况既是省略。总不能因为受贿罪中无此注意规定,就认为无身份犯不构成受贿罪的共犯,这是对法律条文的误解。也对司法实践有相当大的消极影响,不利于反腐倡廉工作的开展。近期的司法判例如2000年北京市第一中级法院审理的成克杰受贿案中,李平本人系香港商人,假如依第一种观点,成克杰定受贿罪,李平就定不了,显然放纵了犯罪。
3、刑法理论中混合主体共同犯罪的概念,也支持了无身份犯可以成为受贿罪共犯的观点。所谓“混合主体共同犯罪”即指有身份者与无身份者共同犯罪。受贿罪的共犯行为就是这类犯罪。混合主体共同犯罪强调的是,虽然二人以上共同受贿罪不要求所有的共同受贿犯罪人均具有特定身份,但至少要有一人是有特殊身份,即国家工作人员。它是有身份者行为与无身份者行为的有机统一。若没有特殊身份的存在,就不可能有利用职务上便利这一行为的发展,也就不成立受贿罪。至于其他人员虽不具备特殊身份,但符合共同犯罪要件,只是由于其中一人的身份,并实施了侵犯国家工作人员职务的廉洁性,由此构成了受贿罪的共犯。
二、受贿罪共犯的主要形式
国家工作人员之间互相勾结、伙同受贿,这种情况构成要件清楚,不必细述。国家工作人员与非国家工作人员互相勾结、伙同受贿,是比较复杂的情况。我在此仅针对典型形式之一:国家工作人员与家属能否构成受贿罪共犯进行研究。
当前,贿赂手段越来越隐蔽。国家工作人员为了逃避法律的追究,许多情况下并不亲自接受财物,而是由其家属出面,收受财物。这种情况下的家属到底可否构成受贿罪的共犯。我认为,应该谨慎处理,不能一概而论。要注意到家属与国家工作人员的特殊关系,家属与国家工作人员共同生活,客观上帮助国家工作人员接受财物,即使是明知的,并有接受贿赂的共同故意行为,光凭这些是不能定罪的。只有当家属是积极地参与,并且帮助的情节非常严重,[3] 才能定罪。具体表现如下:(1)、家属与国家工作人员共同商议、策划,由家属传递信息、勾结关系、接纳财物、甚至事后转移赃物,毁灭罪证,掩饰罪行等。[4] 这时,家属构成了受贿罪共犯的帮助犯,是从犯,应承担相应的刑事责任。(2)、家属不时的诱导、劝说、催促国家工作人员索取、收受财物,国家工作人员在其教唆下产生了受贿犯罪的意图,并实施了受贿行为。这里,家属构成了受贿罪共犯的教唆犯,应承当从犯的次要刑事责任。也就是说,家属仅有代为接受财物行为或者明知国家工作人员收受了贿赂,而与其共享等行为,是不能构成受贿罪共犯的。否则,就扩大了打击面。恐怕一罚国家工作人员,就必罚家属。明显超出了刑法中受贿罪的惩罚目的。

注释:
[1]杨兴培、何萍:《非特殊身份人员能否构成贪污罪的共犯》,载《刑事法学》2002年第3期第75页
[2]张明楷:《非国家工作人员伙同受贿的共犯认定》载《检察日报》2001年11月1日第3版
[3]谢甫成、牛建平《受贿罪认定中值得探讨的几个问题》载《重庆大学学报(社会科学版)》2001年第4期
[4]刘光显、张泗汉主编《贪污贿赂罪的认定与处理》人民法院出版社1996年版
参考书目:
*刘光显、张泗汉主编《贪污贿赂罪的认定与处理》人民法院出版社1996年版
*刘家琛主编《刑法分则及配套规定新释新解》人民法院出版社
*于建伟主编《新编刑事法律适用手册》中国检察出版社



中国银监会关于印发银行业消费者权益保护工作指引的通知

中国银行业监督管理委员会


中国银监会关于印发银行业消费者权益保护工作指引的通知

银监发〔2013〕38号



各银监局,各政策性银行、国有商业银行、股份制商业银行、金融资产管理公司,邮政储蓄银行,银监会直接监管的信托公司、企业集团财务公司、金融租赁公司,中国银行业协会、中国信托业协会、中国财务公司协会:

现将《银行业消费者权益保护工作指引》印发给你们,请遵照执行。





银行业消费者权益保护工作指引



第一章 总则



第一条 为保护银行业消费者合法权益,维护公平、公正的市场环境,增强公众对银行业的市场信心,促进银行业健康发展,保持金融体系稳定,根据《中华人民共和国银行业监督管理法》、《中华人民共和国商业银行法》等法律法规,制定本指引。

第二条 在中国境内依法设立的银行业金融机构适用本指引。

第三条 本指引所称银行业消费者是指购买或使用银行业产品和接受银行业服务的自然人。

第四条 本指引所称银行业消费者权益保护,是指银行业通过适当的程序和措施,推动实现银行业消费者在与银行业金融机构发生业务往来的各个阶段始终得到公平、公正和诚信的对待。

第五条 银行业消费者权益保护工作应当坚持以人为本,坚持服务至上,坚持社会责任,践行向银行业消费者公开信息的义务,履行公正对待银行业消费者的责任,遵从公平交易的原则,依法维护银行业消费者的合法权益。

第六条 中国银监会及其派出机构依法对银行业金融机构消费者权益保护工作实施监督管理。

第七条 银行业金融机构是实施银行业消费者权益保护的工作主体。

银行业金融机构应当遵循依法合规和内部自律原则,构建落实银行业消费者权益保护工作的体制机制,履行保护银行业消费者合法权益的义务。

第八条 银行业消费者有权依法主张自身合法权益不受侵害,并对银行业金融机构消费者权益保护工作进行监督,提出批评和建议,对侵害自身合法权益的行为和相关人员进行检举和控告。

第二章 行为准则



第九条 银行业金融机构应当尊重银行业消费者的知情权和自主选择权,履行告知义务,不得在营销产品和服务过程中以任何方式隐瞒风险、夸大收益,或者进行强制性交易。

第十条 银行业金融机构应当尊重银行业消费者的公平交易权,公平、公正制定格式合同和协议文本,不得出现误导、欺诈等侵害银行业消费者合法权益的条款。

第十一条 银行业金融机构应当了解银行业消费者的风险偏好和风险承受能力,提供相应的产品和服务,不得主动提供与银行业消费者风险承受能力不相符合的产品和服务。

第十二条 银行业金融机构应当尊重银行业消费者的个人金融信息安全权,采取有效措施加强对个人金融信息的保护,不得篡改、违法使用银行业消费者个人金融信息,不得在未经银行业消费者授权或同意的情况下向第三方提供个人金融信息。

第十三条 银行业金融机构应当在产品销售过程中,严格区分自有产品和代销产品,不得混淆、模糊两者性质向银行业消费者误导销售金融产品。

第十四条 银行业金融机构应当严格遵守国家关于金融服务收费的各项规定,披露收费项目和标准,不得随意增加收费项目或提高收费标准。

第十五条 银行业金融机构应当坚持服务便利性原则,合理安排柜面窗口,缩减等候时间,不得无故拒绝银行业消费者合理的服务需求。

第十六条 银行业金融机构应当尊重银行业消费者,照顾残疾人等特殊消费者的实际需要,尽量提供便利化服务,不得有歧视性行为。



第三章 制度保障



第十七条 银行业金融机构应当加强银行业消费者权益保护工作的体制机制建设。

(一)银行业金融机构应当积极主动开展银行业消费者权益保护工作,明确将其纳入公司治理和企业文化建设,并体现在发展战略之中。

(二)银行业金融机构董(理)事会承担银行业消费者权益保护工作的最终责任。

银行业金融机构董(理)事会负责制定银行业消费者权益保护工作的战略、政策和目标,督促高管层有效执行和落实相关工作,定期听取高管层关于银行业消费者权益保护工作开展情况的专题报告,并将相关工作作为信息披露的重要内容。

银行业金融机构董(理)事会负责监督、评价银行业消费者权益保护工作的全面性、及时性、有效性以及高管层相关履职情况。

银行业金融机构董(理)事会可以授权下设的专门委员会履行以上部分职能。获得授权的委员会应当定期向董(理)事会提交有关报告。

(三)银行业金融机构高管层负责制定、定期审查和监督落实银行业消费者权益保护工作的措施、程序以及具体的操作规程,及时了解相关工作状况,并确保提供必要的资源支持,推动银行业消费者权益保护工作积极、有序开展。

银行业金融机构可以结合自身实际,设立由相关高级管理人员和有关部门主要负责人组成的银行业消费者权益保护工作委员会,统一规划、统筹部署整个机构的银行业消费者权益保护工作。

(四)银行业金融机构应当设立或指定专门部门负责银行业消费者权益保护工作。银行业消费者权益保护职能部门应当具备开展相关工作的独立性、权威性和专业能力,并享有向董(理)事会、行长(主任)会议直接报告的途径。

(五)银行业金融机构消费者权益保护职能部门负责牵头组织、协调、督促、指导本级机构其他部门及下级机构开展银行业消费者权益保护工作。

第十八条 银行业金融机构应当建立健全银行业消费者权益保护工作制度体系,包括但不局限于如下内容:

(一)银行业消费者权益保护工作组织架构和运行机制;

(二)银行业消费者权益保护工作内部控制体系;

(三)银行业产品和服务的信息披露规定;

(四)银行业消费者投诉受理流程及处理程序;

(五)银行业消费者金融知识宣传教育框架安排;

(六)银行业消费者权益保护工作报告体系;

(七)银行业消费者权益保护工作监督考评制度;

(八)银行业消费者权益保护工作重大突发事件应急预案;

第十九条 银行业金融机构应当建立健全涉及银行业消费者权益保护工作的事前协调和管控机制,在产品和服务的设计开发、定价管理、协议制定、审批准入、营销推介及售后管理等各个业务环节,落实有关银行业消费者权益保护的内部规章和监管要求,使银行业消费者权益保护的措施在产品和服务进入市场前得以实施。

第二十条 银行业金融机构应当加强产品和服务信息的披露,并在产品和服务推介过程中主动向银行业消费者真实说明产品和服务的性质、收费情况、合同主要条款等内容,禁止欺诈性、误导性宣传,提高信息真实性和透明度,合理揭示产品风险,以便银行业消费者根据相关信息做出合理判断。

第二十一条 银行业金融机构应当积极开展员工教育和培训,帮助员工强化银行业消费者权益保护意识,理解本机构的银行业消费者权益保护工作政策和程序,提高服务技能,丰富专业知识,提升银行业消费者权益保护能力。

第二十二条 银行业金融机构应当积极主动开展银行业金融知识宣传教育活动,通过提升公众的金融意识和金融素质,主动预防和化解潜在矛盾。

第二十三条 银行业金融机构应当为银行业消费者投诉提供必要的便利,实现各类投诉管理的统一化、规范化和系统化,确保投诉渠道畅通。

(一)银行业金融机构应当在营业网点和门户网站醒目位置公布投诉方式和投诉流程。

(二)银行业金融机构应当做好投诉登记工作,并通过有效方式告知投诉者受理情况、处理时限和联系方式。

第二十四条 银行业金融机构应当完善银行业消费者投诉处置工作机制,在规定时限内调查核实并及时处理银行业消费者投诉。对于确实存在问题的银行业产品和服务,应当采取措施进行补救或纠正;造成损失的,可以通过和解、调解、仲裁、诉讼等方式,根据有关法律法规或合同约定向银行业消费者进行赔偿或补偿。

银行业金融机构应当确保公平处理对同一产品和服务的投诉。

第二十五条 银行业金融机构应当加强对投诉处理结果的跟踪管理,定期汇总分析客户建议、集中投诉问题等信息,认真查找产品和服务的薄弱环节和风险隐患,督促有关部门从管理制度、运营机制、操作流程、协议文本等层面予以改进,切实维护银行业消费者合法权益。

第二十六条 银行业金融机构应当制定银行业消费者权益保护工作考核评价体系,并将考评结果纳入机构内部综合考核评价指标体系当中。

银行业金融机构可以委托社会中介机构对其银行业消费者权益保护工作情况进行定期评估,提高银行业消费者权益保护工作的有效性。

第二十七条 银行业金融机构内部审计职能部门应当定期对银行业消费者权益保护工作制度建设及执行情况进行独立的审查和评价。

第二十八条 银行业金融机构应当完善银行业消费者权益保护工作的内部监督约束机制,强化对银行业消费者权益保护工作的内部规章和外部监管要求落实不力的责任追究,根据对银行业消费者合法权益造成侵害的严重程度或危害程度,采取必要的处罚措施,确保银行业消费者权益保护工作各项规定得以落实。

第二十九条 银行业金融机构应当建立银行业消费者权益保护工作的应急响应机制,主动监测并处理涉及银行业消费者权益保护问题的重大负面舆情和突发事件,并及时报告银监会或其派出机构。

第三十条 银行业金融机构应当定期总结本机构银行业消费者权益保护工作的开展情况,将工作计划及工作开展情况按照监管职责划分报送银监会及其派出机构。同时,应当通过适当方式,将银行业消费者权益保护工作开展情况定期向社会披露。



第四章 监督管理



第三十一条 银监会及其派出机构应当按照预防为先、教育为主、依法维权、协调处置的原则,在深入研究国内外金融领域消费者权益保护的良好实践,合理评估我国银行业消费者权益保护实施情况的基础上,制定银行业消费者权益保护工作的总体战略和制度规范,持续完善和健全相关监管体系。

第三十二条 银行业消费者权益保护工作是银行业监管工作的重要组成部分。银监会及其派出机构应当在市场准入、非现场监管、现场检查等各个监管环节充分体现、落实银行业消费者权益保护工作的理念和要求。

第三十三条 银监会及其派出机构承担对银行业消费者权益保护工作的监管职责,通过采取风险监管与行为监管并重的措施和手段,督促银行业金融机构落实银行业消费者权益保护工作的各项要求。

第三十四条 银监会及其派出机构应当组织搭建银行业消费者保护工作的沟通交流平台,调动社会各界力量,利用现有机制和资源,推动构建银行业消费者权益保护的社会化网络,提高银行业消费者权益保护工作的有效性和时效性。

第三十五条 银监会及其派出机构应当充分了解、核实银行业金融机构消费者权益保护体制机制建设情况、工作开展情况及实际效果;建立健全银行业金融机构消费者权益保护工作评估体系,并将考评结果纳入监管综合考评体系,与市场准入、非现场监管、现场检查等监管措施形成联动,督促银行业金融机构履行银行业消费者权益保护工作的主体责任。

第三十六条 银监会及其派出机构应当对银行业金融机构消费者权益保护工作中存在的问题进行风险提示或提出监管意见。

第三十七条 银监会及其派出机构应当督促银行业金融机构对侵害银行业消费者合法权益的行为予以整改和问责。

第三十八条 银监会及其派出机构应当对经查实的侵害银行业消费者合法权益的银行业金融机构采取必要的监管措施,督促其纠正。

第三十九条 银监会及其派出机构应当根据需要对银行业金融机构侵害银行业消费者合法权益的违规行为以及纠正、处理情况予以通报。

第四十条 银监会及其派出机构应当督促银行业金融机构妥善解决与银行业消费者之间的纠纷,并依法受理银行业消费者认为未得到银行业金融机构妥善处理的投诉,进行协调处理。

第四十一条 银监会及其派出机构应当制定银行业消费者教育工作目标和方案,督促银行业金融机构将银行业知识宣传与消费者教育工作制度化。



第五章 附则



第四十二条 本指引由银监会负责解释。

第四十三条 本指引自公布之日起施行。




二0一三年八月三十日